Company Overview
Exicure, Inc. is a biotechnology company that acquired GPCR USA in January 2025 and is currently exploring strategic alternatives to maximize stockholder value.
Key Financial Figures
For the year ended December 31, 2025, the company reported a total revenue of $0. The basic and diluted loss per common share was reported as $(0.79).
Additional Financial Insights
The company recorded a net loss of $4.9 million in 2025. This reflects a decreased loss compared to the prior year, primarily driven by a $6.0 million gain from an early lease termination. Exicure ended the year with $3.7 million in cash and cash equivalents, noting that substantial additional financing is required to continue funding operations.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post Exicure, Inc. 2025 Financial Results Analysis first appeared on Alphastreet.
